The soluble epoxide hydrolase inhibitor AR9281 decreases blood pressure, ameliorates renal injury and improves vascular function in hypertension

Pharmaceuticals

Volumn 2, Issue 3, 2009, Pages 217-227

  Imig, John D ^a   Carpenter, Margaret A ^a   Shaw, Sean ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Eicosanoids; Hypertension; Kidney disease; Soluble epoxide hydrolase; Vascular

Indexed keywords

EID: 78751647808     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph2030217     Document Type: Article

References (33)

1. Spector, A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 2009, 50, S52–S56.
2. Newman, J.W.; Morisseau, C.; Hammock, B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 2005, 44, 1–51.
3. Marino, J.P., Jr. Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery. Curr. Top. Med. Chem. 2009, 9, 452–463.
4. Imig, J.D. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc. Drug Rev. 2006, 24, 169–188.
5. Loch, D.; Hoey, A.; Morisseau, C.; Hammock, B.D.; Brown, L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 2007, 47, 87–98.
6. Jung, O.; Brandes, R.P.; Kim, I.H.; Schweda, F.; Schmidt, R.; Hammock, B.D.; Busse, R.; Fleming, I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45, 759–765.
7. Zhao, X.; Yamamoto, T.; Newman, J.W.; Kim, I.H.; Watanabe, T.; Hammock, B.D.; Stewart, J.; Pollock, J.S.; Pollock, D.M.; Imig, J.D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 2004, 15, 1244–1253.
8. Ghosh, S.; Chiang, P.C.; Wahlstrom, J.L.; Fujiwara, H.; Selbo, J.G.; Roberds, S.L. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin. Pharmacol. Toxicol. 2008, 102, 453–458.
9. Imig, J.D.; Zhao, X.; Zaharis, C.Z.; Olearczyk, J.J.; Pollock, D.M.; Newman, J.W.; Kim, I.H.; Watanabe, T.; Hammock, B.D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005, 46, 975–981.
10. Schmelzer, K.R.; Kubala, L.; Newman, J.W.; Kim, I.H.; Eiserich, J.P.; Hammock, B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA 2005, 102, 9772–9777.
11. Inceoglu, B.; Jinks, S.L.; Schmelzer, K.R.; Waite, T.; Kim, I.H.; Hammock, B.D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 2006, 79, 2311–2319.
12. Olearczyk, J.J.; Quigley, J.E.; Mitchell, B.C.; Yamamoto, T.; Kim, I.H.; Newman, J.W.; Luria, A.; Hammock, B.D.; Imig, J.D. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin. Sci. (Lond) 2009, 116, 61–70.
13. Simpkins, A.N.; Rudic, R.D.; Schreihofer, D.A.; Roy, S.; Manhiani, M.; Tsai, H.J.; Hammock, B.D.; Imig, J.D. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am. J. Pathol. 2009, 174, 2086–2095.
14. Manhiani, M.; Quigley, J.E.; Knight, S.F.; Tasoobshirazi, S.; Moore, T.; Brands, M.W.; Hammock, B.D.; Imig, J.D. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. Renal Physiol. 2009, 297, F740–F748.
15. Yu, Z.; Xu, F.; Huse, L.M.; Morisseau, C.; Draper, A.J.; Newman, J.W.; Parker, C.; Graham, L.; Engler, M.M.; Hammock, B.D.; Zeldin, D.C.; Kroetz, D.L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 2000, 87, 992–998.
16. Hercule, H.C.; Schunck, W.H.; Gross, V.; Seringer, J.; Leung, F.P.; Weldon, S.M.; da Costa Goncalves, A.; Huang, Y.; Luft, F.C.; Gollasch, M. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 54–60.
17. Shen, H.C.; Ding, F.X.; Wang, S.; Xu, S.; Chen, H.S.; Tong, X.; Mitra, K.; Kumar, S.; Zhang, X.; Chen, Y.; Zhou, G.; Pai, L.Y.; Alonso-Galicia, M.; Chen, X.; Zhang, B.; Tata, J.R. Berger, J.P.; Colletti, S.L. Discovery of spirocylic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 3398–3404.
18. Mori, T.; Cowley, A.W., Jr. Role of pressure in angiotensin II-induced renal injury: chronic servo-control of renal perfusion pressure in rats. Hypertension 2004, 43, 752–759.
19. Parrish, A.R.; Chen, G.; Burghardt, R.C.; Watanabe, T.; Morisseau, C.; Hammock, B.D. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol. Toxicol. 2008, 25, 217–225.
20. Motoki, A.; Merkel, M.J.; Packwood, W.H.; Cao, Z.; Liu, L.; Iliff, J.; Alkayed, N.J.; Van Winkle, D.M. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H2128–H2134.
21. Xu, D.; Li, N.; He, Y.; Timofeyev, V.; Lu, L.; Tsai, H.J.; Kim, I.H.; Tuteja, D.; Mateo. R.K.; Singapuri, A.; Davis, B.B.; Low, R.; Hammock, B.D.; Chiamvimonvat, N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA 2006, 103, 18733–18738.
22. Seubert, J.M.; Sinal, C.J.; Graves, J.; DeGraff, L.M.; Bradbury, J.A.; Lee, C.R.; Goralski, K.; Carey, M.A.; Luria, A.; Newman, J.W.; Hammock, B.D.; Falck, J.R.; Roberts, H.; Rockman, H.A.; Murphy, E.; Zeldin, D.C. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ. Res. 2006, 99, 442–450.
23. Franco, M.; Martinez, F.; Rodriguez-Iturbe, B.; Johnson, R.J.; Santamaria, J.; Montoya, A.; Nepomuceno, T.; Bautista, R.; Tapia, E.; Herrera-Acosta, J. Angiotensin II, interstitial inflammation, and the pathogenesis of salt-sensitive hypertension. Am. J. Physiol. Renal Physiol. 2006, 291, F1281–F1287.
24. Zoccali, C.; Mallamaci, F.; Tripepi, G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. 2003, 63, S105–S110.
25. Ruiz-Ortega, M.; Lorenzo, O.; Ruperez, M.; Esteban, V.; Mezzano, S.; Egido, J. Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib. Nephrol. 2001, 135, 123–137.
26. Elmarakby, A.A.; Quigley, J.E.; Olearczyk, J.J.; Sridhar, A.; Cook, A.K.; Inscho, E.W.; Pollock, D.M.; Imig, J.D. Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension. Hypertension 2007, 50, 1069–1076.
27. Muller, D.N.; Shagdarsuren, E.; Park, J.K.; Dechend, R.; Mervaala, E.; Hampich, F.; Fiebeler, A.; Ju, X.; Finckenberg, P.; Theuer, J.; Viedt, C.; Kreuzer, J.; Heidecke, H.; Haller, H.; Zenke, M.; Luft, F.C. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 2002, 161, 1679–1693.
28. Guzik, T.J.; Hoch, N.E.; Brown, K.A.; McCann, L.A.; Rahman, A.; Dikalov, S.; Goronzy, J.; Weyand, C.; Harrison, D.G. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007, 204, 2449–2460.
29. Hoch, N.E.; Guzik, T.J.; Chen, W.; Deans, T.; Maalouf, S.A.; Gratze, P.; Weyand, C.; Harrison, D.G. Regulation of T-cell function by endogenously produced angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296, R208–R216.
30. Kang, K.T.; Sullivan, J.C.; Sasser, J.M.; Imig, J.D.; Pollock, J.S. Novel nitric oxide synthase--dependent mechanism of vasorelaxation in small arteries from hypertensive rats. Hypertension 2007, 49, 893–901.
31. Diep, Q.N.; El Mabrouk, M.; Cohn, J.S.; Endemann, D.; Amiri, F.; Virdis, A.; Neves, M.F.; Schiffrin, E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002, 105, 2296–2302.
32. Schulman, I.H.; Zhou, M.S.; Raij, L. Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. Curr. Hypertens. Rep. 2005, 7, 61–67.
33. Goto, K.; Fujii, K.; Onaka, U.; Abe, I.; Fujishima, M. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000, 36, 575–580.